FIGURE 3.

a) Mean change from baseline (start of double-blind treatment in COMET) in Asthma Control Questionnaire (ACQ)-5 score; b) ratio to baseline in blood eosinophil count; c) mean change from baseline in St George's Respiratory Questionnaire (SGRQ) total score; and d) mean change from baseline in pre-bronchodilator forced expiratory volume in 1 s (FEV₁) (on-treatment; part C; blinded treatment). Week 0 represents 4 weeks following the last dose of open-label mepolizumab. Data are presented as least squares means (95% CI). Patient numbers at each given time point are shown below each graph. Higher scores on the ACQ-5 indicate worse control (range 0–6); a change of 0.5 points is the minimal clinically important difference [15]. Higher scores on the SGRQ indicate a worse function (range 0–100); a change of 4 points is the minimal clinically important difference [16].